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1. Neglected tropical diseases  
 
Neglected tropical diseases (NTDs) are defined as ancient, disabling, and 
poverty-promoting chronic conditions that afflict the poorest people in the 
developing world (1). NTDs have common features, which include high 
endemicity in rural and impoverished areas of Low-Income Countries (LICs), 
as well as the impairment of childhood growth, education, and worker 
productivity (2). The term “neglected” is the best way to define these kinds of 
diseases that have being ignored in spite of their socioeconomic burden. In fact 
these diseases occur among the poorest people where there is no sufficient 
access to medicine or medical help. So far the World Health Organization 
(WHO) has identified 17 NTDs (table 1.1) resulting from four different 
causative pathogens, endemic in 149 countries and affecting more than 1.4 











      Table 1.1 The 17 NTDs, according to WHO (3). 
Pathogens causes Diseases 
Virus Dengue/severe dengue Rabies 
Protozoa Chagas disease Human African trypanosomiasis (sleeping sickness) 
Helminth 
Cysticercosis/Taeniasis 













NTDs affect the lives of about a billion people around the world, especially in 
the African regions, and threaten the health of millions of people. NTDs are 
chronic disabling conditions that kill an estimated 534,000 people every year 
and cause about 62.5 million disability-adjusted life-years (DALYs) (2,3). 
However, due to the nature of the diseases, the lack of sufficient disease 
surveillance and consequently the underestimation of disease incidence, the real 
burden of NTDs is not easy to estimate.  
DALY is a time-based metric explained for the first time in the Global Burden 
of Disease (GBD) 1990 study that measures the gap between an “ideal” healthy 
population and the reality caused by a specific disease, combining both 
premature mortality (years of life lost, YLLs) and disability (years of life lived 





DALY=YLL+YLD (4). YLL takes into account both the frequency of deaths 
and the age at which it occurs. It is calculated from the number of deaths at each 
age multiplied by a global standard life expectancy at the age when death 
occurs. Disabilities are differently weighted so that more severe is the disability 
greater is the number of YLDs that are lost; disability weight is comprised 
between 0 and 1, where 0 corresponds to perfect health and 1 to death (5).  
NTDs, thanks to existing and cost effective medicines as well as the application 
of simple and basic healthy habits, are preventable and eradicable diseases; 
however, medicines are not always available and healthy habits are not so well 
known among the poorest people affected by NTDs (6).  This can be 
understood from the fact that during the period 2000-2011, only 37 of the new 
850 therapeutics products (including vaccines, biological, fixed-dose 
combinations, new indications, new formulation, new chemical entities), which 
account for 4% of the total products, were approved for neglected diseases. 
Moreover, in the same period just four of the 336 new chemical entities 
approved were for neglected diseases (7). These data are in line with the 
evidence reported in the study conducted to scrutinize pipelines for NTDs 
between 2005 and 2012. According to this report, only 650 clinical studies were 
conducted for NTDs, not numerically comparable with pipelines addressing 
influent diseases (e.g. 15,232 clinical trials for cardiovascular diseases and 
10,063 clinical trials for respiratory diseases). The study also reported a 
growing number of trials in the period 2011-2012, and  diseases like 
leishmaniasis, dengue, rabies, and salmonella were the most investigated (8). 
Recently, more efforts have been made to tackle these debilitating diseases that 
are being recognized as major public health problems. The WHO recommends 
the simultaneous implementation of five public-health strategies for the 





• Preventive chemotherapy; 
• Intensified case-management;  
• Vector control;  
• Safe water, sanitation and hygiene provision;  
• Veterinary public health.  
The need to tackle NTDs was embraced by governments and donors, including 
the pharmaceutical companies and nongovernmental organizations (NGOs), 
investing in preventing and controlling this diverse group of diseases. In 
January 2012 two important events strengthened the attention being given to 
NTDs and their eradication (by 2020): the London Declaration with the help of 
22 partners, including WHO and the major pharmaceutical companies 
committed to sustaining the eradication of 11 of 17 NTDs; and the WHO 
programme entitled “accelerating work to overcome the global impact of 
neglected tropical diseases; a roadmap for implementation”. The purpose of 
these interventions is to guide and implement strategies and policies, 
highlighting the importance to put an end to NTDs by the end of 2020 (9).  
Even if the attention to these diseases in recent years has grown even more 
becoming a major public health issue, the efforts started at the end of the ‘80s, 
when the private and public sectors have merged to create a cost-effective, 
feasible and effective collaboration: the Public-Private Partnerships (PPPs).  
PPPs are recognized as being useful because they combine drug donations from 
the private sector with the public intervention for administrating, advocating 
and coordinating activities at local level. These particular diseases need the 
implementation of different activities that require a broader intervention.  
PPPs can intervene at different levels, depending on the issue to address. They 
have been established to either develop a new product for unmet needs or 





interventions. Medicine for Malaria Venture, International AIDS Vaccine 
Initiative, and the Global Alliance for TB Drug Development are examples of 
PPPs established to fund research in developing medicines for specific diseases 
(10). 
PPPs have also been implemented to address NTDs through specific drug 
donation programmes (DDPs), adopting strategies aimed at reaching the 
greatest number of people affected and eradicating the disease. DDPs have been 
applied in different contexts, including short-term responses to emergencies, 
such as natural disasters, donations of existing inventory and donation in 
response to specific diseases (11). DDPs represent a sustainable way of 
donating a specific treatment, applying vertical programmes (also known as 
stand-alone, categorical or free-standing programmes or the vertical approach) 
to enable medicine access especially in the case where drug costs are not 
affordable, and donations by private sector represent the only solution (12). 
Vertical health programmes refer to instances where “the solution of a given 
health problem is addressed through the application of a specific measure 
through single-purpose machinery”(13). On the contrary, integrated 
programmes (also known as horizontal programmes, integrated health services 
or horizontal approaches) seek to “tackle the overall health problems on a wide 
front and on a long-term basis through the creation of a system of permanent 
institutions commonly known as general health services” (14). In recent years, 
the debate has been focused on identifying which kind of strategies, between 
vertical and integratated programmes, is better to apply in the case of NTDs to 
finally eradicate them. 
Through DDPs Mass Drug Administration (MDA) strategies have been 
implemented, allowing the distribution of medicines donated by pharmaceutical 





applicable, MDA is also adopted for the realization of Preventive 
Chemotherapy (PC), first introduced by WHO to prevent transmission or 
morbidity of human helminth diseases through drugs distribution (16), and 
subsequently adopted by DDPs.  
PC is characterized by (i) population-based diagnosis, (ii) population-based 
treatment and (iii) implementation at regular intervals (17).  
Africa is the most affected area by NTDs, in both the sub-Saharan Africa 
regions and many other tropical and subtropical areas where there is an overlap 
of NTDs; at least five to six neglected tropical diseases occur in the same 
region, leading to a polyparasitized population (18). 
Trachoma, LF, onchocerciasis, schistosomiasis and the three major soil-
transmitted helminths diseases (STHs), including ascariasis, trichuriasis and 
hookworm) are the seven mostly widespread NTDs in Africa that exhibit 
considerable geographic overlap. Therefore, they can be controlled and in some 
cases eliminated by four effective treatments through MDA, applying PC on a 
large-scale: ivermectin, albendazole, azithromycin and praziquantel (2,18). 
These treatments are currently donated through PPPs already operating in 
parallel in Africa:  ivermectin for the treatment of both onchocerciasis and LF, 
that is also effective against Ascaris and Trichuris infections, and represents the 
standard treatment for human strongyloidiasis; albendazole is used for the 
treatment of LF, STH and hookworm; azithromycin is effective in tackling 
trachoma; and praziquantel is used for schistosomiasis and STH. The 
overlapping of these NTDs and the possibility to control them with just four 
treatments gives the chance to establish integrated control programmes. In 
addition, the four-drug regimen would also target ectoparasite infections, such 
as scabies, pediculosis, tungiasis, and cutaneous larva migrans, and their 





For the control and elimination of these selected diseases, WHO recommends 
implementing PC as an effective strategy, integrating it with other interventions 
such as: management of morbidity; vector and intermediate host control; 
provision of safe water supply, sanitation and hygiene (9).  
The most important DDPs managed through PPPs are representing by the 
Mectizan Donation Programme (MDP), the Global Programme to Eliminate 
Lymphatic Filariasis (GPELF), and International Trachoma Initiative (ITI). 
The MDP is a PPP that donates ivermectin, thanks to the contribution of Merck, 
for the control of onchocerciasis and LF where they are co-endemic. The 
GPELF distributes albendazole for LF donated by GlaxoSmithKline (GSK), 
that is also donated by MedPharm through the Schistosomiasis Control 
Initiative, a PPP based in London and operating locally in different countries in 
Africa, that distribute albendazole in combination with praziquantel regimen 
(21).  
So far, the PPPs seem to be an effective strategy to overcome NTDs. MDP is 
the first DDP established through a PPP, founded in 1987 by Merck & Co. for 
the distribution of ivermectin (Mectizan®) “wherever is needed for as long as 
needed” primarily for the control and subsequently for the elimination of 
onchocerciasis (22).  
In response to the WHO call to eliminate blinding trachoma by 2020 
(GET2020), the ITI was founded in 1998 thanks to the contribution of Pfizer, 
the donor of azithromycin (Zithromax®), and the Edna McConnell Clark 
Foundation. 
In 2000 the WHO launched the GPELF; this initiative was embraced by GSK, 
who decided to collaborate with WHO donating albendazole (Albenza®) for 
the control of the disease, followed by Merck who contributed with ivermectin 





Based on the WHO plan for accelerating work to overcome the global impact of 
NTDs, onchocerciasis falls into diseases group for which eradication in Latin 
America is feasible by 2015; the elimination of trachoma and LF are expected 
by 2020, estimating the elimination of blinding trachoma in 75% of countries 
affected, and the 100% of elimination in the case of LF (9).  
Other important examples of DDPs founded to overcome NTDs are: Children 
without Worms for global control of STH, established in 2006 by the Task 
Force for Global Health and Johnson & Johnson who committed themselves to 
donating up to fifty million doses of mebendazole annually (24); since 2000 
Novartis in collaboration with WHO supports the global fight against leprosy, 
donating multidrug packages of dapsone, rifampicin, and clofazimine (25). In 
2001 Sanofi Aventis decided to collaborate with WHO, donating multidrug 
therapy packages of pentamidine, melarsoprol, and eflornithine for the 
treatment of sleeping sickness (26). 
 
1.1. The drug donation programme based on PPPs 
 
1.1.1.  The Mectizan Donation Programme 
Onchocerciasis, also known as river blindness, is a parasitic disease caused by 
the filarial worm Onchocerca volvulus that affects eyes and skin, transmitted 
through the bites of infected Simulium blackflies. The parasites that cause 
onchocerciasis are transmitted from human to human, and adult onchocerca 
volvulus worms can live for fifteen years in the human body.  Prevention is 
based on vector control to kill the larvae of the blackfly vector using 





African countries, representing the world’s fourth leading cause of preventable 
blindness after cataracts, glaucoma and trachoma, and the second largest cause 
of infectious blindness. It also causes ugly skin disfigurement with 
depigmentation, severe itching and swelling that have serious socio-cultural 
implications. The manifestation of the disease includes impaired vision, 
blindness and chronic dermatitis. Definitive diagnosis of onchocerciasis is made 
by examination of skin biopsies for microfilaria. The treatment of 
onchocerciasis is based on a single yearly dose of ivermectin (Mectizan®). 
Africa represents the most afflicted region for onchocerciasis, where 99% of 
people infected by O. volvulus live in 31 sub-Saharan African countries; 
another 12 foci were found in 5 regions of Latin America: Brazil, Ecuador, 
Guatemala, Mexico, Venezuela (27). According to these latest data, 
onchocerciasis is estimated to be endemic in 37 countries (28). The impact of 
onchocerciasis includes lost economic productivity, diminished earning, 
















Figure 1.1 Distribution of onchocerciasis worldwide, 2013. 
 
(29). 
Ivermectin is an anthelmintic agent for oral administration indicated in the 
treatment of onchocerciasis caused by O. volvulus, as well as for the treatment 
of microfilaremia caused by Wuchereria bancrofti infection, the causative agent 
of LF. The recommend dose is annual or twice yearly to all non-pregnant adults 
and children <15 Kg  (30). 
In response to this emergency situation, in 1987 Merck decided to donate 
ivermectin for the treatment of onchocerciasis for as long as necessary wherever 
it is needed. In 1998 Merck expanded its donation for the treatment of LF in 28 
African countries and in the Yemen where onchocerciasis and LF resulted co-
endemic (31).  With this aim in mind, MDP was born, a PPP that resulted in a 
multisectoral coalition between Merck & Co., the Mectizan Expert Committee 
(MEC), the Task Force for Child Survival and Development, WHO, the World 





Health (MoH), more than 35 non-governmental development organizations, and 
thousands of local community health workers (32). 
The MDP built up a strong governance both at central and local level. At 
international level the MDP Secretariat and the Mectizan Expert Committee are 
present, ready to collaborate with regional coordination programs in Africa and 
America (33). 
The principal purposes of the program are: 
• Assure availability of ivermectin for the treatment of onchocerciasis; 
• Provide good medical practice; 
• Approved prescribing procedures, including the monitoring of adverse 
reactions. 
These aims have been implemented adopting and supporting MDA, vector 
control, surveillance, reports and advocacy about activities. 
In order to manage the drug distribution and collateral activities with the 
intervention of local bodies, the Onchocerciasis Control Programme in West 
Africa (OCP) was born (1974-2002), the African Programme for 
Onchocerciasis Control (APOC) was launched in 1995, and the Onchocerciasis 
Elimination Program for the Americas (OEPA) begun in 1992. These 
programmes are all still operating (33). 
The OCP was established between WHO, World Bank, the UN Development 
Programme, the UN Food and Agriculture Organization, NGOs and more than 
25 donors. It succeeded in eliminating onchocerciasis as a public health 
problem adopting vector control through insecticides and drug distribution in 10 
African endemic countries.  
APOC is a partnership between donors, NGOs, the UN agencies and member 
countries, with the WHO as the executive agency, MDP as provider of 





within a period of 15-20 years, an effective and self-sustainable community-
directed treatment (CDT) in the endemic areas of the 19 member countries, 
principally for morbidity control. More recently APOC fixed the new goal of 
eliminating onchocerciasis where possible by 2025 (34). In 2012, APOC 
estimated that 76.4% of the at-risk population had been covered by ivermectin 
treatment (35). CDT is a project conceived in 1996 thanks to the intervention of 
WHO, World Bank, and Special Programme for Research and Training 
Disease, with the collaboration of African scientists, in order to find a more 
sustainable and cost-effective method for treatment delivery. CDT was formally 
implemented for the first time in 1997 by APOC. According to an APOC 
report, 447 million doses of treatment have been administered, and CDT 
projects are operated in 91% of the APOC area, protecting 96% of the 94 
million people targeted with an overall treatment coverage of 89% (36). Both 
Colombia and Ecuador interrupted transmission of river blindness in 2007 and 
2009 respectively. In 2011 also Guatemala and Mexico stopped transmission 
(28).  
Along with the distribution of ivermectin, MDP adopted different tools 
specifically implemented for onchocerciasis. In response to the need of APOC 
to determine the exact geographical distribution of onchocerciasis, WHO’s 
Special Programme for Research and Training in Tropical Diseases (TDR) 
developed a rapid assessment method in 1993, the Rapid Epidemiological 
Mapping of Onchocerciasis (REMO). It based on geographical information, 
especially on the presence of river basins, to identify communities likely to be 
at a high risk of infection. Using REMO, it is possible to define the hyper and 
meso-endemic areas where the community nodule prevalence is ≥ 20%. This 
was followed by other tools for mapping the disease to predict high risk 





distance from breeding sites; one of these is the Rapid Epidemiological 
Assessment (REA) that establishes treatment priorities by counting nodules. 
OCP and others found that the prevalence of nodules in a cohort of adult males 
multiplied by 1.5 is a reasonable estimate of the community prevalence of 
onchocerciasis while the Rapid Assessment for procedure for Loa Loa 
(RAPLOA) was developed by UNICEF, TDR, United Nation Development 
programme (UNDP) and financed by APOC. RAPLOA based on a 
questionnaire on the history of visible worms moving in the lower part of the 
eye, predicting whether or not loiasis is present at high levels in a community 
(33). 
More than others, CDT represents the most important intervention that makes 
the distribution of ivermectin feasible and reachable also among the remotest 
areas of endemic countries. MDP is the first program that has been able to 
improve delivery strategies, starting from passive distribution (where drugs 
were delivered at the health centers), through mobile teams (where paid local 
health professional are responsible for drug distribution), to community-based 
distribution (CBD), and the CDT called, in the case of ivermectin distribution, 
CDTI. This last strategy represents a milestone in the DDPs, because the result 
was a cost effective intervention able to involve communities in the distribution 
of treatments, enhancing their consciousness about the disease and the 
importance of treating it. CDTI represents the main pillar of drug distribution, 
because it implies the involvement of communities also at decision level (37.)  
In the case of ivermectin, once a community has decided to adopt the CDT, the 
MoH and NGOs train a health worker; in turn, the health worker runs a training 
programme for the community that institutes their own Community-Directed 
Distributor (CDD), who is trained to: 





• Detect and treat minor side effects; 
• Refer cases of severe adverse events to the nearest health facility; 
• Fill in household treatment forms; 
• Keep records; 
• Report about the treatment campaign; 
• Know the criteria for exclusion to ivermectin treatment; 
• Organize the storage and management of the ivermectin tablets (38). 
In terms of drugs delivered, thanks to the MDP between 1,5 billion treatments 
for onchocerciasis have been donated, treating about 700 million people, from 
when it was started to 2012 (39, 40). The achievements of MDP can be 
understood through the activities carried out by the two organizations that 
independently operated in Africa: OCP and APOC. The activities of OCP, that 
among the others also includes advocacy, community support and drug 
distribution, were successful in preventing blindness in 600,000 people, 
reducing the level of infection in 40 million blind people and reclaimed 250,000 
km2 of abandoned land (27). In 2006, thanks to OEPA, the 13 foci of regions 
where the program is operated achieved more than 85% of ivermectin coverage, 
and transmission was interrupted in 10 out of 13 foci by the end of 2011 (41).  
In the APOC area over 100 million people received regular treatment for 
onchocerciasis by the end of 2012. Since inception, the programme has 
recorded an 86% reduction of unrelenting itching, 39% reduction in infection 
prevalence of the disease, prevention of more than 500,000 cases of blindness 
and an estimated economic rate of return (ERR) of 17% on invested funds. ERR 
is often calculated as the Net Present Value (NPV) of the stream of net benefits 
equal to zero. If the ERR is greater than the market interest rate or the cost of 
borrowing money, then the programme is determined to be an economically 





standard for successful public health programmes (43). About 185,000 
communities distributed ivermectin, representing an overall geographic 
coverage of 95.4%, and the prevalence of infection has been reduced by about 
73% compared with pre-APOC levels. Annual treatment with ivermectin in 
APOC countries has increased from 1,5 million in 1997, to 68.4 million in 
2009, nearing the projected target of 90 million by 2015 (36).  
Referring to the year 2000, OCP spent a total $13.9 million in 11 countries in 
West Africa; among these vector control is the component that influences to a 
major extent accounting for $9.2 million. 
In the same year the total costs of APOC were estimated at $9.4 million in 19 
member countries throughout Africa, where $5.9 million of this amount was 
spent on national ivermectin distribution projects, carried out in 13 of 19 APOC 
countries. 
While a significant portion of OCP expenditure was for vector control, for 
APOC’s activities this represents a minimal part. 
The cost effectiveness of APOC activities was calculated at US$14-$30 per 
DALY averted. However, the economic benefit is sensitive to the fact that the 
drug has been donated free of charge. (42). WHO has found that treatment cost 
of ivermectin is US$0.57 per person, yielding a 17% ERR.  
Based on cost data collected in savannah foci in Ghana, it was estimated that 
the economic cost of annual CDTI is $41,536 per target population of 100,000 
individuals per year (2012 prices) (34).  
The sustainability of MDP and CDTI has been assessed much more than other 
programmes and activities, both in quantitative and qualitative studies.  
A recent study estimated APOC financial cost between 1995 and 2010, 
excluding cost of drugs. MDA with ivermectin averted 8.2 million DALYs (3.2 





impairment) in APOC areas, at a nominal cost of about US$257 million. The 
study analyzed data on pre-control prevalence of infection and population 
coverage of mass treatment, simulating trend in infection, visual impairment, 
blindness, and severe itch through the micro-simulation model ONCHOSIM. 
According to calculations, MDA against onchocerciasis accounted for about a 
nominal US$31 per undiscounted DALY averted between 1995 and 2010. If 
expected health gains and costs for the period 2011-2015 are included, mass 
treatment accounts for $27 per DALY averted. According to WHO guidelines, 
this is highly cost-effective, as it is below the GDP per capita of most countries 
covered by APOC (27-1,545 international dollar per capita, Global health 
Observatory Data Repository, accessed 2 August, 2012). These results indicate 
that cost per treatment with ivermectin in APOC areas is affordable, at US$0.51 
per treatment, excluding cost of donated drugs (44).  
Remme and colleagues estimated that the predicted cost of CDTI in APOC 
countries during 15 years of activities was US$145 million referring to 
international donor community plus US$64 million referred to MoH, giving a 
total US$209 million. They estimated that the CDTI cost (excluding drug costs) 
is approximately US$7 per DALY averted. Assuming that 70% of endemic 
communities will ultimately be covered by CDTI and 80% of those 
communities will maintain annual treatment at 65% coverage for at least 15 
years, at least 26 million DALYs would be prevented over a 25-year period 
(45). Conteh estimated that CDTI cost US$9 per DALY averted; Laxminarayan 
reports that CDTI costs US$6 per DALY averted, when the drug has been 
provided free of charge. (46, 47). Onwujekwe et al conducted a study in the 
villages of Nike and Achi in Nigeria they estimated treatment cost to be $0.17 





direct financial costs, opportunity costs, advocacy, mobilizing the community, 
training and distribution (48). 
Onchocerciasis is the fourth leading cause of blindness worldwide, having a 
huge socioeconomic impact among populations. Blindness, visual impairment 
and onchocercal skin disease (OSD) primary impact in lost productivity, 
diminished earnings both among people affected and among caregivers, adverse 
effects on the supply of labour, and reduced agricultural output due to the 
exodus from arable land (46). This can be defined through the data emerged in 
the multicountries study conducted in 1997 by the World Bank on the economic 
impact of the OSD, including two sites in Nigeria and one in both Sudan and 
Ethiopia respectively. This study is based on a matched-pair prospective design 
comparing OSD and non-OSD persons, including the costs of health-related 
expenditures at individual and community levels, productivity, transportation, 
non-cash exchanges, and time spent in seeking health care and accompanying 
patients. From the study it emerged that on average, persons suffering from 
OSD were found to spend an additional $8.10 over a 6-month period in 
comparison to their non-OSD counterparts from the same community, and 
spend an additional 6.75 h seeking health care over the same 6-month period. 
The average per-capita annual expenditures for health in Nigeria, Sudan and 
Ethiopia are $23, $48 and $25 respectively (50). These results are comparable 
with data obtained in the study conducted by Kim in 1997, on the earnings of 
425 permanent workers of Teppi coffee plantation in southwest Ethiopia. Data 
emerged showing that those workers who are not affected by OSD earned on 
average $5.32 in 2001 US dollar more per month than workers with severe 
OSD. This difference was statistically significant (P< 0.05). The amount 





days of work per month in comparison with who are not affected by the disease 
(42). 
Amazigo et al in 2007 conducted a study to evaluate the performance of the 
communities under the CDTI activity, with particular interest in determining 
whether or not the community participation and ownership really existed in the 
CDTI project development. They defined ownership as follow: “evidence of the 
ability of the community to own and manage CDTI; participation of community 
members and their leadership in decision-making; initiating and supporting 
CDTI implementation” (51). When this study took place there were 41 projects 
in 10 countries that had distributed ivermectin through CDTI from three to five 
times over a set period, and all of these projects are included in the study. 
Much of the information about community level was collected in situ, using 
semi-structured interviews with community members, CDDs and their leaders, 
and/or from direct observation. Other information was collected also at higher 
levels, including health facility support indicators. For each country evaluation 
members came from both internal and external levels, including the CDTI 
project coordinators from the regional and/or district levels of the health 
system, onchocerciasis researchers, specialists from the NGDO coalition, and 
representatives from the donors. The evaluation was based on nine community-
level sustainability indicators and relative evaluation instruments. 
To assess the routine project activities and process:  
• Planning: evaluate planning and managing of CDTI by CDDs and 
community authorities; 
• Leadership: evaluate how community leaders managed problems 
associated with distribution and evaluation of communities involvement 





• Monitoring &Supervision:  evaluate whether CDDs reported complete 
and accurate distribution data; 
• Mectizan Supply & Distribution:  evaluate whether the drug was 
obtained and managed effectively by the community; 
• Training, health education, sensitization, advocacy, mobilization 
(TRHSAM). 
To assess resources available to projects: 
• Financing: evaluate whether the community supported the CDDs and 
CDTI; 
• Human resources: evaluate the willingness to help by the community 
members; 
• Transport and material resources: evaluate the transportation of 
Mectizan provided by community. 
To assess the therapeutic coverage: 
• Coverage:  the proportion of eligible population who had received 
ivermectin in a given year. (65% being the threshold required to achieve 
control within 15 years). 
For each project, the performance of the community and health care providers 
were rated using qualitative and quantitative indicators predicting sustainability. 
Each indicator is scored from 0 when no progress has been made toward 
sustainability, and scores between 1 and 4 indicate slight to full progress toward 
sustainability. The result showed that at community level, over 70% of projects 
received satisfactory sustainability scores of 2.5 or more. It is important to 
highlight that sustainability indicators had the highest score when communities 
had the most control; by contrast, the indicator where communities depended on 





Another qualitative study was conducted by Burnham and Mebrahtu in 2004 in 
order to clarify organizational structures and governance functions using semi-
structured interviews with key informants and self-administered survey of staff 
involved, among 21 international organizations and 34 individually staffed 
persons. They received completed surveys from 25 persons using a survey 
based on the four-point Likert scales, ranging from 1 (no benefit) to 4 (major 
benefit). The objective of the study is to assess the benefits, problems, costs, 
governance and management of the MDP from the partner’s viewpoint. Three 
important factors emerged when analysing the institutional relationships among 
the partners that contributed to the success of the programme:  
• Each participating organization perceived benefits from its collaboration 
with the other institutions involved in the program; 
• The relationship between Merck and MDP has been characterized by 
transparency and communication, and the visibility and credibility of the 
MDP’s first chairman strengthened the relationship with Merck and 
other organizations; 
• The clear separation of Merck’s role in providing and shipping the drug 
from Expert Committee and Secretariat’s role of providing technical 
expertise and management of the donation program (33). 
	  
The key issues raised from this qualitative evaluation are the following: 
• Gender: despite the efforts of APOC to encourage women to take part in 
the implementation of community distribution, the majority of 
community-selected distributors tend to be male; 
• Treatment costs: from the inception of MDP, Merck tried to provide 
ivermectin free of charge, but this was not always possible. It was 





Latin America or when MDA has been part of a multinational 
programme as in the case of OCP. Where cost recovery systems were 
subsidized by national policy, the MDP decided to allow charges for the 
delivery of ivermectin, maintaining the drug at no cost. The APOC has 
taken a position against paying incentives for distribution, encouraging 
communities to support distributors directly; 
• Records: one of the major difficulties experienced in APOC areas has 
been the inability to obtain accurate community census data to provide 
the denominator in the calculation of ivermectin coverage rates; 
Monitoring:  in OCP countries a strong monitoring program was in 
place from the beginning, and there was a good data management 
capacity built by the WHO/OCP. The data flow begins with treatment 
reports sent by the community distributors to the health facility level 
where they are summarized. NGOs play a key-role in motoring 
programs, particularly where first-line health facilities are weak or 
absent. At the APOC level, it is planned that monitoring teams visit 
country projects twice during their 5-year cycle to assess progress 
towards achieving objectives. Community-based monitoring approach is 




1.1.2. International Trachoma Initiative 
Trachoma is an infectious disease caused by Chlamydia trachomatis that is 
responsible for about 3% of cases of blindness worldwide. It still represents the 





estimation, 7.3 million people have trichiasis (eye lashes touching the cornea); 
229 million people are at risk of infection worldwide, and 21 million of active 
cases have been estimated. In endemic areas more than 21 million people need 
antibiotic treatment, about 7 million people required surgery and 2.2 million are 
visually disabled, of whom 1.2 million have become irreversibly blind (52). 
Trachoma is a chronic disease, characterized by repeated or persistent infection 
of the superior tarsal epithelial cells of conjunctiva. The diagnosis of the disease 
is possible through rapid and efficient laboratory methods not available in the 
endemic countries, so the diagnosis is usually made clinically. To simplify the 
detection, WHO developed a grading system based on signs and the extent of 
the inflammation, conjunctival thickening and scarring, trichiasis, and corneal 
opacity, based on five different stages: 
• 1st: Trachomatous Inflammation-Follicular (TF): the presence of five or 
more follicles in the upper tarsal conjunctiva. 
• 2nd: Trachomatous Inflammation-Intense (TI): pronounced inflammatory 
thickening of the tarsal conjunctiva that obscures more than half of the 
normal deep tarsal vessels. The TF and the TI stages are also defined as 
Active Trachoma. 
• 3rd: Trachomatous Scarring (TS): the presence of scarring in the tarsal 
conjunctiva. 
• 4th: Trachomatous Trichiasis (TT): defined as at least one eyelash 
rubbing on the eyeball. 
• 5th: Corneal Opacity due to trachoma (CO): easily visible corneal 
opacity over the pupil. 
Active Trachoma as Trachomatous Inflammation-Follicular and /or 
Trachomatous Inflammation-Intense (TF/TI) were also defined within this 





According to latest data, 51 countries are known or suspected to be endemic to 
blinding trachoma in Asia, Central and South America, Australia and the 
Middle East. Africa has the higher prevalence, accounting for the 77% of 
prevalence worldwide: of the 46 African countries, 29 are thought to be, or have 
been endemic and report the major numbers of cases of trachoma: 18.2 million 
cases of active trachoma (representing the 85.3% of all cases globally) and 3.2 
million cases of trichiasis (44.1% of all cases globally). Ethiopia and South 
Sudan have been reported the highest prevalence. (54). 




ITI is PPPs that support the WHO initiative called the Alliance for Global 
Elimination of Trachoma by the year 2020 (GET2020), and it is also a member 





focused on strengthening national trachoma control programs, collaborating 
with national institutions, NGOs agencies and partners with the aim of 
eliminating blinding trachoma by 2020. As for the MDP, also the ITI was able 
to structure the governance at central level with the Board of Directors, the ITI 
Secretariat and the Trachoma Expert Committee (TEC), an independent body of 
seven internationally recognized experts in the field of public health, 
ophthalmology, blindness prevention and SAFE strategy implementation (56).  
The principle mission of ITI based on the distribution of azithromycin, 
implementing the “A” component of the SAFE strategy, promoting surgery for 
trichiasis (the advanced stage of trachoma), providing technical assistance and 
mobilizing resources for trachoma control programs.  
The SAFE strategy was launched in 1997 by WHO, and includes: 
• Surgery for trichiasis:  directed at the TT stage of the disease, the 
immediate precursor of blindness. Ophthalmic assistants and nurses 
could perform the simple and quick surgery procedure after a training 
period of 2 weeks, using local anesthetic. The procedure itself takes 
about 15 minutes and long-term success rates are around 80% (57). 
• Antibiotic azithromycin: antibiotic is used for active disease, TF or TI 
stages. Before the introduction of Zithromax, the treatment was based 
on a topical preparation of tetracycline, however the ointment must be 
applied to the eye twice a day for 6 weeks. Trachoma control 
programmes use antibiotics for two reasons: first, to treat individually 
infected people, and secondly, to limit transmitting the infection to 
others. Because many people who are infected do not have signs of the 
disease on examination, mass treatment of all individuals living in a 
community seems a good approach to reduce the transmission of 





• Facial cleanliness: this approach is helpful to break the cycle of 
reinfection and helps to stop the spread of disease, especially among 
children. Despite the previous components, this, and the environmental 
improvement approach are focused on preventing transmission. 
• Environmental change to increase access to water and sanitation: the 
disease is known to be highly correlated with poverty, lack of personal 
and community hygiene, limited access to healthcare and water. 
Interventions include provision of water and control of flies (57). 
Azithromycin donation is feasible thanks to the contribution of Pfizer; it is a 
macrolide antibiotic for oral administration, effective in a single dose therapy 
(20 mg/kg body weight), and represents the first-line antibiotic chosen for the 
treatment of trachoma due to Chlamydia trachomatis bacterial.  
The application process for azithromycin is started nearly eighteen months 
before the drug arrives in the recipient country. ITI works directly with national 
trachoma program managers who are nominated by the MoH (58).  
The distribution of antibiotics is made through MDA. WHO has developed 
guidelines for drug distribution, firstly based on determining the prevalence of 
follicular trachoma at district-level in children with 1 to 9 years old. If the 
prevalence of active trachoma (1st or 2nd stages of trachoma) is 10% or higher, 
mass treatment with antibiotics must be carried out on all people throughout the 
district, and should continue for at least 3 years and should not stop until the 
prevalence of TF in children aged 1-9 years is below 5%. If the baseline 
prevalence is 30% or more, annual treatment should be undertaken for at least 5 
years before review. Where the prevalence falls below 10%, treatment is 
recommended only in those communities with a prevalence ≥10% (59).  
Along with the donation of azithromycin, ITI holds several activities that 





• Collaborating with MoH, governmental and NGOs, to support the “A” 
element; 
• Promoting Surgery for trichiasis, “facial cleanliness” and 
“environmental improvement”; 
• Providing technical assistance to countries and partner organizations, 
including logistical assistance; 
• Mobilizing resources for trachoma control programmes; 
• Integrating trachoma control into approaches to control and eliminate 
the other NTDs; 
• Advocating for trachoma to be included in a wider programmes at 
global level . 
Despite the involvement of international bodies, it has been recognized that 
most countries have not yet implemented programmes to eliminate blinding 
trachoma by 2020. In order to meet these gaps, a new tool has been developed, 
the Trachoma Action Plan (TAP). TAP represents a useful template that was 
able to delineate specific actions to undertake and milestones to reach by 
individual nations. To date, this has been successfully implemented in most 
trachoma endemic countries in Africa (60).  
Even though efforts have been made to eliminate trachoma by 2020, the 
estimation of trachoma distribution represents, still today, a big issue that leads 
to an unrealistic epidemiology data about the disease. To overcome this 
obstacle, different tools have been developed for gathering data regarding the 
prevalence of trachoma, to find out the geographical distribution of trachoma, 
of primary importance for planning, implementing, monitoring and evaluating 
the trachoma control programmes (61).  
These tools include:  





• Population-based Prevalence Surveys (PBPS); 
• Acceptance Sampling Trachoma Rapid Assessment (ASTRA);  
• Integrated threshold mapping (ITM). 
TRA was developed by WHO as a rapid and inexpensive method used to 
determine community priority for treatment; although ASTRA is not widely 
used, it is useful to classify communities in relation to a threshold value. 
PBPS is the most widely used method since it provides a representative 
measure of the prevalence of trachoma within a population. The ITM is the 
most recent method developed and takes into account sampling of school 
children, pre-school children and women of childbearing age to determine 
whether the prevalence of trachoma (also applicable to other NTDs) falls under 
a specific threshold (61, 62). 
National data indicates that about 45 million people were treated for trachoma 
in 2010, and 52 million in 2011, mainly using azithromycin plus tetracycline 
eye ointment (61). Morocco represents the first country that achieved the 
Ultimate Intervention Goals (UIG) in 2006, eliminating trachoma. Gambia and 
Ghana are part of the African countries that are in the post-endemic surveillance 
stage (63, 64).  
According to WHO’s latest data, the countries which have reported the 
successful outcome indicator targets are Gambia, Ghana, Iran, Morocco, 
Myanmar, Oman and Viet Nam. These outcome indicator targets for 
elimination of blinding trachoma as a public health problem are: 
• <1 case of TT “unknown to the health system” per 1000 total 
population; 






Impact assessment data reported by ITI based on countries level data, highlight 
that where TF baseline prevalence is 30% and above in children aged 1-9 years, 
even 5 years of SAFE intervention is insufficient to reduce TF to less than 5%, 
and reduce the prevalence of TT in the whole population to less than 0.1% (65).  
In spite of the efforts made during the meeting of WHO GET2020 in 2011, it 
was recognized that most countries were not yet developing their plans to 
eliminate blinding trachoma by 2020 (66). The lack of information about 
trachoma epidemiology derives form a lack of knowledge about the 
geographical scope of disease, therefore it is essential, and of great importance, 
to know where intervention is necessary. To plan surgery for trichiasis, as part 
of the SAFE strategy, it is essential to know the prevalence of trichiasis, and 
also the implementation of the other activities, including MDA, based on the 
recognition of the prevalence of active trachoma. With the aim of overcoming 
the knowledge gap about epidemiology data, not reachable through the tools 
which already exist, the project Global Trachoma Mapping Project (GTMP) has 
been funded. The team project works with MoH, and it is scheduled to end by 
2015. Based on GTMP, each suspected endemic area is subdivided into 
“evaluation units” which contain 100,000-250,000 people. Then, a PBPS of 
more than 20 clusters is undertaken among each evaluation unit. Data are 
collected based on water and sanitation at household level, age, gender and 
presence or not of trachoma signs at individual level (67). 
After validation, obtained data are than collected and displayed on the web-
based Global Atlas of Trachoma. It provides regularly updated, open-access 
district-level prevalence maps of the current status of trachoma prevalence (68).  
The year 2013 has been signed with an important progress toward the global 
MDA coverage. In fact, the global administrative coverage (the number of 





districts in which MDA was planned) was 83% (387/466), including 53 districts 
involved in antibiotic treatment for trachoma for the first time in 2013 (54). 
Through the ITI, during its first 15 years of activities, Pfizer has donated more 
than 340 million doses of azithromycin to 28 countries in Africa and Asia.  
Evans conducted a cost effectiveness analysis of implementing trachoma 
control programmes in Myanmar, considering only direct costs. The study 
reports a total of US$54 per case of visual impairment prevented, and US$47 
per case of visual impairment prevented including only non surgical costs 
(mostly antibiotic treatment) (69). 
Conteh estimated that the implementation of the strategy account for US$5-100 
cost per DALY averted (46).  
Frick and colleagues have made two different estimates about the economic 
cost of trachoma, framed in terms of lost productivity. The economic cost of 
one disabled person due to trachoma was calculated by multiplying the value of 
the disability weights by the individual economic productivity value for each 
country considered. In the first report the productivity lost was estimated at US$ 
2.9 billion referring to the year 1995. The economic loss estimated in the 
second report was higher at US$ 5.3 billion referring to the year 2003, using the 
adjusted dollar value for 2003, considering the productivity lost from blindness 
to be 100% instead of 60% as in the first study and it added a 10% cost for each 
blind person for carers. The authors also examined the effect of including 
trichiasis and found that the lost productivity rises significantly to US$ 8 billion 
(70).  
In order to assess a qualitative evaluation of the ITI activities implementation, 
in 2001 the London School of Hygiene & Tropical Medicine (LSHTM) 
undertook an evaluation of ITI-supported trachoma control activities in eight 





Vietnam. The aim of this project was to conduct participatory evaluations in the 
eight countries selected, in order to evaluate the effectiveness, efficiency, 
adequacy, and impact of the four components of the SAFE strategy. 
Semi-structured interviews were conducted at central level, focused on 
gathering opinions about the strengths and weaknesses of the programme, in 
particular its structure and planning; instead the interviews conducted at 
regional and district levels were focused on the analysis of strengths and 
weaknesses of the implementation of the programme.  
This study reported that a major obstacle to programme planning is lack of 
detail about trachoma endemicity. With the exception of Morocco, the national 
coverage of trachoma control activities, including antibiotic distribution, was 
insufficient compared with the magnitude of the disease burden. High-quality 
mass distribution of antibiotics was observed in most countries even in 
extremely resource-poor settings. The antibiotic coverage within communities 
generally exceeded 80%, and this appeared to be due in part to the high 
community acceptance of antibiotics. Inadequate water and sanitation remained 
a major problem in all programmes areas, in each of the countries. Monitoring 
of SAFE activities was generally poor, either because the indicators collected 
were inappropriate, or because systems were not in place for reporting from the 
community to the district, and on to national level (71). 
 
1.1.3. Global Programme to Eliminate Lymphatic Phylariasis 
LF, also known as elephantiasis is one of the oldest and most debilitating 
NTDs. It is caused by the filarial nematodes Wuchereria bancrofti, Brugia 





most diffused in Africa, transmitted to humans through the mosquito’s bites 
(72).  
Although LF rarely causes death, it is a major cause of suffering and disability, 
leading to painful and disfiguring chronic enlargement of arms and legs, 
comprise children, representing the secondo cause of disability worldwide. The 
disease can result in different kinds of manifestations: adenolymphangitis 
(inflamed lymphatic vessels), lymphedema (abnormal accumulation of lymph 
fluid in the tissues), elephantiasis (disfiguring swollen of limbs), and hydrocele 
in males. 
According to WHO data, about 120 million people in the tropical and sub-
tropical areas are infected with LF. 
Globally, about 73 countries are endemic and 1.39 million people at risk require 
preventive chemotherapy. South-East Asia and Africa are the most affected 
regions. WHO reports that among the 73 endemic countries, 68 have completed 
mapping their endemic foci, 11 countries have made progress and 2 have yet to 



















China and the Republic of Korea were declared to have eliminated LF as a 
public health problem in 2007 and 2008, respectively.  
The GPELF is a PPPs established in 2000 between GSK and WHO, for the 
donation of albendazole free of charge for as long as needed to eliminate LF as 
a public health problem in endemic area by 2020. Albendazole represents the 
gold standard for the treatment of LF, in combination with diethylcarbamazine 
citrate (DEC) or in combination with ivermectin in area where LF is co-
endemic with onchocerciasis.  
The governance of GPELF is composed by WHO, the Technical Advisory 
Group (TAG) established by WHO to provide expert advice to the GPELF, and 





address specific technical issues; in 2002 the PRG was decentralized to the LF 
Regional programme review Group (RPRG). The Global Alliance to Eliminate 
Lymphatic Filariasis (GAELF) was established in 2000 supporting and assisting 
the GPELF in advocacy, mobilizing resources and coordinating partners. (75).  
The primary goals of the programme are: 
• The eradication of LF as a public health problem by 2020, through the 
MDA interrupting the transmission; 
• The control of morbidity, alleviating and preventing the suffering of 
people affected by the disease. 
The MDA aims to treat the entire population at risk for a period long enough to 
ensure that the levels of microfilariae in the blood remain below those 
necessary to sustain transmission. To attain the first goal, four main strategies 
have been defined: 
• Map the geographical distribution of the disease; 
• Implement mass drug administration (MDA) annually for 5 years; 
• Implement surveillance post MDA; 
• Verify the elimination of transmission. 
(76). 
In addition, WHO developed four steps to follow in order to interrupt 
transmission: 
• Areas suspected of being endemic are mapped to determine the 
geographical distribution of the disease and identify area where MDA 
have to be implement; 
• MDA is implemented and continued for at least 5 years to reduce the 
number of parasites in the blood to levels that will prevent mosquito 





• Surveillance is implemented after MDA is discontinued to identify areas 
of ongoing transmission or recrudescence; 
• If criteria are met, the elimination of the disease is verified (3). 
Mapping the disease is of primary importance to know the area to treat and 
distribute the drug. Determining the presence of LF is easy to do through Rapid 
Immunochromatographic Card test (ICT). It is a rapid, highly sensitive and 
specific finger prick test blood for W. bancrofti circulating Og4C3 antigen, used 
as community serologic surveys, to determine the target areas for MDA (77). 
The relative expensive cost represents the only disadvantage, costing US$1.50, 
so the surveys are made in the geographic scope (78,79).  
Also for GPELF, MDA is the elected method for the distribution of 
albendazole, as part of the PC global strategy, reaching all eligible people in 
endemic areas where the prevalence of LF is greater than 1% (78). The aim of 
MDA is the reduction of microfilaria prevalence and density in the blood. The 
regimens recommended by WHO are: 
• Once-yearly treatment with a single dose of two medicines co-
administered, albendazole 400 mg plus either ivermectin (150-200 
µg/kg) or albendazole plus DEC (6mg/kg) for a period of 4-6 years, 
because this period corresponds to the estimated reproductive life span 
cycle of adult worms; 
• Exclusive use of table and cooking salt fortified with DEC for a period 
of 1-2 years. This latter regimen has led to the successful elimination in 
China, representing a challenge to implement and expand in other 
settings  
LF is co-endemic with Loiasis in nine countries, impeding MDA in these areas 
due to the severe adverse reactions that ivermectin causes in presence of loiasis 





MDA, GPELF includes both MDA and Vector Control (VC), especially in co-
endemic areas where ivermectin cannot be used. VC is feasible and plays an 
important complementary rule both in the MDA and post-MDA surveillance 
phase (80). 
Different kinds of strategies have been implemented to reach target populations 
including door-to-door distribution or delivery through fixed post, schools, 
workplaces and other central points. The CDT strategy is the strategy of choice 
also for LF, called Community Directed treatment with ivermectin plus 
Albendazole (CDTI+). Normally community volunteers perform it after they 
have taken a “village census” and training activities (81). 
MDA has been implemented in 60 countries, of which 15 have reduced 
infection prevalence, stopped MDA and started surveillance. 22 countries 
achieved the 100% geographical coverage, conducting MDA in all endemic 
areas of the country, and 23 are conducting MDA but without covering all 
endemic areas. Since 2000, a cumulative total of 4.9 billion doses of medicines 
have been delivered to 1 billion people (82). WHO also reported that during 
2013, the programme targeted 563.5 million people through PC and treated 
around 410 million people, accounting for 72.8 of coverage (83). 
An estimated 19.5 million preschool-aged children between 2 and 4 years of 
age, and 101 million school-aged children between 5 and 14 years of age were 
treated globally. In order to verify the MDA state, sentinel and spot check site 
surveys are routinely conducted to monitor and evaluate the population reached, 
and also to determine if MDA can be stopped and post-MDA surveillance can 
start. Transmission assessment survey (TAS) is a new tool used for 6-7 year old 
children to guide programme manager decision-making in order to stop MDA. 
A programme area, the Implementation Unit (IU) is considered eligible for TAS 





been implemented; (ii) coverage exceeds 65% of the total population in the IU 
for each of five rounds of MDA; and (iii) the prevalence of infection in sentinel 
and spot-check sites is below 1% (assessing microfilaremia) or below 2% 
(assessing antigenemia, usually by ICT test). Once an area passes the TAS 
requirements, post-MDA surveillance begins (80).  
Over the first 8 years, it has been calculated that more than 6 million cases of 
hydrocele and 4 million cases of lymphedema were prevented, and about 32 
million DALYs averted (84). 
The effective strategy to tackle LF resides in the implementation of MDA and 
in the control of morbidity of people already affected, including lymphedema, 
elephantiasis, or hydrocele. The control of morbidity aimed to reduce the 
burden of disease and preventing disability (81). 
Another study estimated the cost of MDA for LF across 7 countries: Burkina 
Faso, Ghana, Egypt, Tanzania, the Philippines, the Dominican Republic, and 
Haiti. The cost analysis protocol was designed to estimate the total annual cost 
of the national MDA program cost for LF including training, mapping, 
mobilization, distribution, monitoring, and surveillance, the average cost per 
person treated, and the relative contributions of the endemic countries and the 
external partners. The study includes both economic costs per person treated 
(all resources used in the program, including donated materials and drugs) and 
financial costs per person treated (the actual cash disbursements for a program 
including resources provided by the national government and local communities 
but excluding the donated materials). The study adopted the national 
programme perspective, so including both direct and indirect costs due to LF, 
beginning from the year 2000, calculating the costs in local currencies and 
converted in US dollars for the final analysis. This study shows that the 





donated materials) ranged from US$ 0.06 to US$ 2.23 while economic costs 
(that is financial cost plus the value of donated materials) varied between US$ 
0.40 and US$ 5.8. MDA coverage ranged from 53% to 91%. It has been 
calculated that the average delivery cost of MDA per person in Haiti is 
US$0.44; but taking into consideration the drug donation and purchases, the 
average cost per person increase to US$0.68. The most substantial cost 
components included per diem (35% of total economic costs), supplies (14% of 
total economic costs) and personnel (7% of total economic costs) (85). 
A study conducted by Remme, estimated the cost of intervention for the 
elimination of LF, onchocerciasis and Chagas disease and leprosy. In the case 
of LF they evaluated cost assuming three different scenarios about the MDA 
duration: 6 years, 10 years, and 30 years. The MDA cost US$4-8 per DALY 
averted for the first and second scenario and US$29 if MDA continued for 30 
years (47, 86). 
A meta-analysis conducted by Chu et al in 2010, investigated the benefits 
gained from the GPELF interventions in economic terms, including the direct 
treatment costs, indirect costs of lost-labour, and costs of health system to care 
affected individuals. The population taken into account for this economic study 
is divided into two groups: those protected from acquiring infection, and 
subsequent disease; those already infected but protected from disease 
progression. These two groups are segmented into four sub-populations, 
constituting the “benefit cohort population”. According to this study, an 
estimated US$21.8 billion of direct economic benefits will be gained over the 
lifetime of 31.4 million individual treated during the first 8 years of GPELF 
activities. It was calculated that 94% of these benefits result from preventing the 
indirect costs in terms of lost of working time, and US$2.2 billion will be saved 





reduction in the cost of providing services to patients (direct costs). Direct 
treatment costs refer to medicines, consultation fees, transport, food, 
accommodation; indirect labour costs refer to income lost as a result of reduced 
hours and economic activity due to LF morbidity.  
The ERR of return of GPELF is considered high, estimated to be between $20 
and $30 per individual for every $1 invested, recognizing this programme a 
cost-effective investment for health system  (84). 
The cost of MDA to treat the entire at risk population for 5-7 years in areas 
where prevalence in >1% has been calculated in the Conteh et al study, 
estimated to be $5-10 cost per DALY averted to interrupt transmission and 




























2. Outline of the thesis 
The aim of the thesis is to explore the most important DDPs established so far 
and to conduct an impact assessment of their implementation: MDP founded by 
Merck & Co. in 1987 for tackling onchocerciasis through the donation of 
ivermectin; the ITI established to overcome blinding trachoma through the 
donation of azithromycin thanks to the PPP established in 1998 between Pfizer 
Inc. and the Edna McConnell Clark Foundation; the GPELF to combat LF 
through the donation of albendazole, founded in 2000 by GSK and WHO.  
The choice of framework on which the impact assessment was based, derives 
from a retrospective analysis of the available literature, topics and data mostly 
used to describe the  NTDs and DDPs impact. These qualitative and 
quantitative data were categorized into three major dimensions  that cover 
health, organizational and economic aspects. The literature analysis led to 
gathering information about the NTDs characteristics and burden, DDPs health 
achievements and economic analyses. However, due to the differences on study 
frameworks, criteria of analysis adopted, and variability about data available it 
was not possible to build a direct comparative analysis of the three DDPs 
included.  
For the health impact the widely parameters used are: diseases endemicity; 
morbidity and mortality; number of people treated with MDA; total amount of 




of DALY averted. These data were mostly derived from DDPs and WHO 
website and reports.  
The economic impact analysis include: the economic burden of the disease, 
principally in terms of productivity loss; programmes expenditures, including 
implementation cost, MDA, and treatment costs; cost per DALY; cost per 
DALY averted; cost per person treated; cost benefits in terms of economic 
gains and reduction expenditure thanks to the reduction of disease prevalence.  
Even though programmes were carried-out with different implementation 
strategies and developed specific management tools, reviewing the literature 
some activities commonly developed by DDPs emerged: drug delivery 
strategies; tools for mapping disease distribution; eligible population inclusion 
criteria; governance at central and local level. These dimensions are included in 
order to describe organizational impact and programme management. In 
addition, qualitative evaluation studies based on semi-structured interviews 
were conducted for ITI and MDP. For MDP two different studies, evaluating 
the CDTI sustainability and governance management were conducted. The 
qualitative study about ITI assessed its activities implementation and 
sustainability. 
Comparing the aspects described above, limits and strengths of programmes 
and studies conducted emerged, building a critical analysis of DDPs analyzed. 
The literature research conducted on PubMed includes articles in the English 
language published between 1994 and 2014. Keywords used in the research 
included: “neglected tropical diseases”, “NTDs”, “Mectizan Donation 
Programme”, “MDP”, “Global Programme to Eliminate Lymphatic Filariasis”, 
“GPELF”, “International Trachoma Initiative”, “ITI”, “onchocerciasis”, 
“trachoma”, “lymphatic filariasis”. These were used separately or in 
combination with the following keywords: “epidemiology”, “economic 




“cost(s)”, “DALYs”, “cost per DALYs”, “cost effectiveness”. Exclusion criteria 
for literature selection were not adopted. Grey literature from Google, WHO 
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The PhD research project is focused on DDPs for NDs. These programs are 
usually implemented within a public-private partnership (PPP) framework.  
Under the umbrella of a PPP, a variety of collaborations are developed, often 
with huge differences regarding objectives, governance structure, stakeholders’ 
involvement, and operations. The objectives of a PPP could be: 
• The development of new products for ND (e.g. Medicine for Malaria 
Venture (MMV), the International AIDS Vaccine Initiative, and the 
Global Alliance for TB Drug Development)  (1). 
• The donation or subsidizing a product to control a specific disease; 
• The improvement of products quality or regulation; 
• Strengthening health services. 
Disease-specific donation programs built on a PPP in a long-term commitment 




was the Mectizan Donation Program (MDP), established by Merck & Co. in 
1987 and concluded in 2003, and donated ivermectin (Mectizan) for the control 
of onchocerciasis “wherever is needed, for as long as needed” (2). Other 
remarkable examples of PPP are the International Trachoma Initiative (ITI) 
founded by Pfizer Inc. and the Edna McConnell Clark Foundation in 1998 in 
which Pfizer provided azithromycin (Zithromax) as part of a wider program to 
eliminate trachoma, and the Global Program to Eliminate Lymphatic Filariasis 
(GPELF) established in 1998 by GlaxoSmithKline and the WHO, in 
collaboration with Merck, which donated albendazole (Albenza) with either 
diethylcarbamazine (DEC) or ivermectin (3). DDPs are focused on delivering 
drugs, but they usually pursue broader objectives, including administration and 
distribution systems, training, health education, and monitoring activities (4). 
The current PhD project aims at (i) reviewing the literature on impact 
assessment of the three above-mentioned DDPs (MDP, ITI, and GPELF) (ii) 
scrutinizing the impact of a project (SMS for Life, within the Novartis Malaria 
Initiative project) aimed at improving the access to medicine for NDs in LIC. 
This section is focused on the first part of the project.  
 
Methods and materials 
The impact assessment of DDPs includes three dimensions: health 
achievements, economic impact, and organizational issues.  
The health impact is measured through (i) the final outcome: avoided burden of 
disease (Disability Adjusted Life Years, DALYs, and number of working days 
lost), and health expectancy, and (ii) the process outcome: the number of people 
reached and the number of treatments delivered. 
The economic impact may be focused on the costs of the program and the 




benefits and costs of drugs (cost-effectiveness analysis) and the program (cost-
benefit analysis). 
The organizational impact usually concerns governance issues of the PPP, 
disease mapping, drug delivery strategies, the relationships among the actors 
involved, and activities aimed at supporting local communities. 
This review covered the full spectrum of impact analyses, with a focus on the 
relationships among partners both at international and national levels, the drug 
delivery strategies, and the evidence on programs cost-benefit. 
The literature review was conducted from September 2011 to March 2012. Both 
peer-reviewed articles (through Medline) and grey literature (DDP websites and 
WHO reports) were considered. The keywords used to investigate the literature 
where: Onchocerciasis, Lymphatic filariasis, Trachoma, Ivermectin, 
Albendazole, Zhitromax, Mectizan, Mectizan Donation Program, International 
Trachoma Initiative, Global Program to Eliminate Lymphatic Filariasis, Public-
Private Partnership for health, Burden of disease, Health impact, Economic 
evaluation, Cost benefits analysis, Cost-effectiveness analysis, Governance, 
Community-based treatment, Drug Distribution Strategy. 
 
 The Mectizan Donation Program (MDP) 
Onchocerciasis, also known as river blindness, is a disfiguring parasitic disease 
that affects eyes and skin transmitted through the bites of infected black flies. It 
represents the second highest infection cause of blindness worldwide, being 
endemic in 35 countries among sub-Saharan Africa, parts of Central and South 
America and in Yemen. Ivermectin is an anthelmintic agent indicated for the 
treatment of onchocerciasis and LF where LF is co-endemic with 
onchocerciasis. There are approximately 37 million people affected by this 




onchocerciasis in 2004 were about 375,000 in Africa, 1,000 in the Americas 
and 11,000 in the Eastern Mediterranean (6). 
The MDP is a PPP founded in 1987 by Merck and the WHO, the Task Force for 
Child Survival, the World Bank, the UNICEF and more than 35 non-
governmental development organizations (2). The primary aim of the project 
was the donation of ivermectin for the treatment of onchocerciasis. In 1998, the 
donation was expanded to include the treatment of lymphatic filariasis (LF) in 
28 African countries and in Yemen, where onchocerciasis and LF are co-
endemic (7). The program was closed in 2003. In addition to its main purpose 
as a DDP in the endemic countries, its co-objectives were to provide good 
medical practices and promote appropriate prescribing behavior. 
From an organizational viewpoint, an independent committee (the Mectizan 
Expert Committee), composed of seven experts in international public health 
and tropical diseases, and an MDP Secretariat were created at the central level 
to appropriately coordinate the project. Existing initiatives on onchocerciasis 
have been incorporated to avoid duplication and distrust from the local 
communities. In Africa, the Onchocerciasis Control Program (OCP) and the 
Africa Program for Onchocerciasis Control (APOC) represented the local 
committees. The OCP was established in 1974 and ended in 2002. The APOC 
was founded in 1995 and will continue until 2015 and is still carrying out the 
activities begun by the MDP. As far as the Americas are concerned, the 
Onchocerciasis Elimination Program for the Americas (OEPA) was integrated 
into the overall approach. This program, founded in 1990, includes six endemic 
countries: Brazil, Columbia, Ecuador, Guatemala, Mexico, and Venezuela.    
As for drugs delivery strategies a Mass Drug Distribution (MDD), supported by 
vector control, surveillance, reporting and advocacy activities, has been 
implemented (8). More specifically, the project started with a passive 




and finally converged toward Community-Based Treatment (CBT). In addition, 
disease mapping was performed to estimate communities at risk. Disease 
mapping has relied on divers tools, including the Rapid Epidemiological 
Mapping of Onchocerciasis (REMO), the Rapid Epidemiological Assessment 
(REA), and the Rapid Assessment for Procedure for Loa Loa (RAPLOA). 
Through this approach, ivermectin was actually distributed to the communities 
living in the endemic countries. The success of this strategy is indirectly 
demonstrated by the circumstance that most of the subsequent donation 
programs have adopted it.  
 
The International Trachoma Initiative (ITI) 
Trachoma is a chronic bacterial disease transmitted from human to human that 
still represents the most common infectious cause of blindness worldwide, 
despite the fact it is preventable and treatable. Azithromycin represents the first-
line antibiotic for the treatment of trachoma, based on a single dose regimen (9, 
10). According to the WHO data, about 84 million people, mostly women and 
children, have active trachoma; around 8 million are visually impaired, 8.2 
million people have an advanced stage of the disease, called trichiasis, and 1.3 
million are blind from trachoma. Trachoma is endemic in 55 countries and 
about half of the global burden is concentrated in 5 countries: Ethiopia, India, 
Nigeria, Sudan, and Uganda. In 2004, Trachoma DALYs were estimated as 
1,334,000 worldwide, and 601,000 in Africa (6). 
The ITI is a PPP founded in 1998 by the Edna McConnell Clark Foundation 
and Pfizer Inc. The mission of ITI is to eliminate blinding trachoma by 2020, by 
adhering to the Alliance for Global Elimination of Trachoma by the year 2020 
(GET 2020), a WHO initiative set up in 1998 and supported by ITI (11). 




(Zithromax), the first-line antibiotic for the treatment of trachoma. The ITI is 
part of a broader mission aimed at tackling trachoma. In particular, it represents 
the implementation of the component “A” of the "SAFE" strategy, launched by 
the WHO in 1997, which includes surgery to correct trichiasis, donation of 
Zithromax, facial cleanliness to prevent disease transmission, and 
environmental change to increase access to clean water, sanitation, and the 
control of flies. 
The collaboration between the Edna McConnell Clark Foundation and Pfizer 
began in the 1990s by providing support for pilot studies in Egypt and Zambia 
to test the effectiveness of Zithromax in children affected by active trachoma. 
The success of the studies intensified the relationship between Clark 
Foundation and Pfizer that culminated with the birth of the ITI.   
ITI is governed by a Board of Directors, the Trachoma Expert Committee 
(TEC) and the ITI Secretariat. The TEC is an independent body of seven 
international experts in the fields of public health, ophthalmology, and 
blindness prevention. The ITI secretariat supports the TEC activities and the 
Board of Directors, coordinating technical assistance in program planning, 
monitoring and evaluating, and manages the application process for ITI support 
(8; 12). 
Like MTD, the ITI has been particularly active in disease mapping and drug 
delivery strategy. Disease mapping has relied on three different methods: the 
Trachoma Rapid Assessment (TRA), the Population-based Prevalence Surveys 
(PBPS) and the Acceptance Sampling Trachoma Rapid Assessment (ASTRA). 
Despite these increasing efforts to map the true occurrence of trachoma, the 
prevalence is still rather unclear and very difficult to capture (13). The drug 
delivery strategy focused on an appropriate management and distribution of 
Zithromax. The application for drug donation starts nearly eighteen months 




whether there are program gaps and gives the local Minister of Health an 
opportunity to review their country plans (14). Treatment delivery has relied on 
WHO guidelines on MDD; according to these, a community should receive 
mass antibiotic treatment when the prevalence of active trachoma is 10% or 
more in children aged ≥10 years, and should continue for at least 3 years until 
the prevalence of TF in children aged 1-9 years is below 5%.  
 
The Global Program to Eliminate Lymphatic Filariasis 
(GPELF) 
LF, also known as elephantiasis, is one of the oldest and most debilitating ND, 
transmitted to humans through mosquito bites. Although it rarely causes death, 
it represents a major cause of suffering and disability, leading to painful and 
disfiguring chronic enlargement of the arms and legs of people, from children to 
adults (15). LF treatment is based on the administration of an annual, single 
dose of diethylcarbazine citrate (DEC) or albendazole plus DEC or ivermectin 
(16). LF is endemic in 83 countries, affecting about 1.3 million people, mainly 
living in the Southeast Asia Region (67%) and Africa (30%). The WHO 
estimated 5.9 million DALYs due to LF at global level (3.5 million in Asia, 2.2 
million in Africa) (6).  
The GPELF was launched in 2000 as a PPP between the WHO and 
GlaxoSmithKline (GSK). The partnership aims at eradicating LF as a public 
health problem by 2020 through the donation of albendazole (Albenza) by GSK 
and alleviating pain and preventing disability caused by LF (17). The GPELF 
was anticipated by different events that increased the awareness on LF 
eradication. In 1993, the International Task Force for Disease Eradication 
included LF in the list of the eradicable or potentially eradicable diseases. In 




toward eliminating LF as a public health problem”. The formal collaboration 
between GSK and WHO, by providing albendazole free of charge for as long as 
needed to eliminate LF, was strengthened by the donation of ivermectin by 
Merck & Co., a drug also used for the treatment of LF, particularly where it is 
co-endemic with onchocerciasis. 
The governance structure of GPELF is very complex. More than 27 
international partners assist and support this PPP. This complexity has driven 
the founders to create a new PPP (Global Alliance to Eliminate Lymphatic 
Filariasis, GAELF) in 2000, to manage advocacy, coordinate partners and 
mobilize resources; this initiative also involved the Minister of Health of the 81 
endemic countries, NGOs, and international organizations (17). The WHO and 
the Technical Advisory Group (TAG) that advices WHO on the relevant key 
issues, together with the GAELF, are the main components of the GPELF 
governance. At regional level, the activities are supported by the Global 
Program Review Group (Global PRG). 
Delivery strategies and implementation of the donation program are mainly 
coordinated by the WHO, with the support of GAELF. Disease mapping, 
assuring MDD, assessing outcome of the national programs, and surveillance 
initiatives were the main focus of implementation. Disease mapping has relied 
on a finger prick rapid blood test, named Rapid Immunochromatographic Card 
Test (ICT), and used for community serologic (18). An MDD has been carried 
out for at least 5 years. Door-to-door distribution, distribution through fixed 
posts and schools, and community-based distribution were implemented, the 
latter being the most successful. Despite the fact that prevention was another 
important part of the program and behavioral measures, including the 
improvement of hygiene habits, are essential to avoid the disease, only 27 





Impact assessment of the three PPPs   
The impact assessment of PPP for ND may consider health achievements, 
organizational impact, and economic impact. 
Health achievements can be measured with process outcome or final outcome 
indicators. Process outcomes include the number of treatments delivered and 
target population covered. Thanks to MDP more than 1.5 billion ivermectin 
tablets have been donated, with more than 700 million people treated (20). 
Pfizer has provided more than 225 million antibiotic treatments for the 
implementation of the “A” component of the SAFE strategy to eliminate 
blinding trachoma. In 2006, Morocco announced the elimination of trachoma as 
a public health problem, followed by Ghana in 2008. Through the GPELF, 
GSK donated 1 billion tablets of albendazole and Merck donated 780 million 
ivermectin treatments for LF (6), but the target population covered is still 
unknown.  
As far as the organizational impact is concerned, this impact strongly depends 
on each PPP's scope. All the relevant diseases are not life threatening and are 
preventable. Hence, treatment availability and affordability are as important as 
actions, which aim at improving behavioral and environmental risk factors. In 
all programs, drug donation has been integrated with other activities. The MDP 
implemented vector control activities to enhance the disease eradication. The 
GPELF has been focused on the interruption of the transmission and the 
management of morbidity, with a special attention to hygiene habits. The ITI 
program is part of a wider strategy that includes actions aimed at increasing 
access to safe water and sanitation and initiatives to improve hygiene habits to 
prevent disease transmission. 
Another common feature of the three programs is the central role played by 




successfully developed tools for mapping the relevant disease, in the case of 
trachoma, disease mapping was not good enough to identify appropriately the 
target population.  
Distribution strategies have mostly relied on MDD and CBT. CBT was 
introduced by the MDP. This approach empowers communities in the endemic 
countries, giving to them adequate information to get involved in decision-
making, organization, and mobilization of resources. Through the CBT, the 
communities become accountable for delivering the treatment by deciding how, 
when, and by whom the treatments should be administered. The success of this 
strategy led to its use for the control of malaria, LF, schistosomiasis, eye care, 
maternal and child health, nutrition, and immunization in various countries (21). 
As for trachoma, despite the fact that the delivery strategy has not been 
sufficiently described, an impact assessment of ITI was carried out by the 
London School of Hygiene & Tropical Medicine (LSHTM) in eight countries 
(22). The current research project detected positive achievements (i.e. MDD of 
high-quality antibiotics) in most countries even in extremely resource-poor 
settings, with a target population coverage within communities generally 
exceeding 80%. However, a lack of detailed data of trachoma endemicity and 
poor monitoring activities of the SAFE were highlighted. In addition, 
inadequate water and sanitation have remained a major problem. 
Whereas all the PPPs considered have created strong governance at the central 
level, only the MDP implemented an integrated strategy with the involvement 
of regional organizations. Three independent organizations were integrated into 
the program: the OEPA in the Americas, the APOC, and the OCP in Africa. 
The APOC is still working in Africa and represents an important institution for 
the eradication of onchocerciasis. According to a 2004 survey, the 21 partners 
involved in the MDP felt satisfied with and perceived benefits from the 




Merck’s role in providing and shipping the drug and the Expert Committee and 
Secretariat’s role in providing technical expertise (23). 
Different studies have been carried out on the costs and economic benefits of 
the three PPPs scrutinized. The economic benefits are usually expressed as 
avoided DALYs by the program. 
There are several economic analyses on MDP, even if mainly focused on the 
first period of the program implementation in Africa and considering APOC 
and OCP separately. However, the studies show important discrepancies, 
depending on costs included and the time horizon considered. The WHO 
estimated an average 850,000 DALYs averted per year thanks to the APOC 
activities, with a cost of USD 9 per DALY averted (6). Another set of studies 
measured the value for money of the program in terms of Economic Rate of 
Return (ERR), the discount rate that sets the net present value of the stream of 
net benefits equal to zero. A public health program with a 10% ERR is 
considered successful by the World Bank. The WHO estimated a ERR of 20% 
for OCP in 1974-2002 and 17% for APOC in 1996-2008. Another set of studies 
has shown a huge increase in the labor productivity thanks to MDP (23, 24). 
The evidence on the economic impact of other programs is poorer than those for 
MDP. In addition, economic impact assessment of ITI on trachoma suffers from 
a limited availability of reliable data on the disease sequelae prevalence in the 
endemic population and the paucity of robust population-based surveys for 
estimating the number of affected people (25). 
The overall economic benefit of the GPELF during the period 2000-2007 is 
estimated at USD 24 billion, with a cost per DALY averted per person of USD 
5.90 (26). The cost of the SAFE strategy for trachoma has been estimated at 
USD 54 per case of visual impairment prevented (27). The implementation of 




blindness are supposed to lose 100% productivity, the 2003 economic loss due 
to trachoma was estimated at USD 5.3 billion (27). 
Summary of the evidence on impact assessment  
 
 
The literature review on the impact assessment of DDPs carried out by a PPP 
has shown important achievements, even if some results are controversial, 
especially for ITI program for trachoma. Despite the fact that health 
achievements and the economic impacts are most important targets of these 
programs, the literature stressed the relevance of the governance structure and 
delivery strategy. Long-term sustainable control of NDs through active PPP 
requires a huge commitment from all partners involved, integration between 
central governance and regional institutions, and an accurate definition of the 
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4. Conclusion  
The PPPs analyzed differ in the strategies and governance they have adopted, 
the stakeholders involved and population reached. However, being a vertical 
programme, MDP, ITI and GPELF aim to focus on the control and elimination 
of a single disease through the long-term commitment of pharmaceutical 
companies, and have established common activities through which it has been 
possible to reduce the social and economic burden of the diseases (27). The 
attention of international stakeholders has grown even more in recent years, due 
to three greatly influencing features of NTDs: they are poverty-promoting; there 
are low-cost and highly cost-effective control approaches that might eliminate 
some of the diseases and create universal access to essential medicines; 
moreover, the full control of these diseases would have simultaneous and 
sustainable effects on poverty reduction (87).  
 
4.1. Health and organizational impact 
The analysed PPPs, along with drug donation have adopted managing, 
reporting, advocating and surveillance activities projected on the base of disease 





control activities in OCP areas for enhancing the eradication of the disease, it 
has also established CDTI, training of CDD, and monitoring activities (32). 
The GPELF has two aims: to interrupt the disease transmission and manage 
disease morbidity. One of the key elements that might contribute to the 
successful elimination of LF by 2020 is the ability of the treatment to not only 
reduce disease morbidity, but also halt the progression of early subclinical 
disease in those already infected (2).  
ITI is focused on delivering the antibiotics needed, thus implementing the “A” 
(i.e. antibiotics) component of the SAFE strategy.  
Thanks to MDP more than 1.5 billion ivermectin tablets have been donated 
(88). Pfizer has provided about 340 million antibiotic treatments for the 
implementation of the “A” component as part of the SAFE strategy and, as a 
result of this donation, in 2006 Morocco was the first country that announced 
the elimination of trachoma as a public health problem, while Gambia and 
Ghana are still in the post-endemic surveillance stage (63, 64). Through the 
GPELF, a cumulative average of 4.9 billion treatment doses have been donated 
(82). It has been estimated that thanks to GPELF more than 32 million DALYs 
have been averted (89), while in the APOC areas about 8.2 million DALYs, 
between the period 1995-2010 have been averted (44). 
 Due to the nature of the programmes, managed by international bodies and 
addressing health problem affecting poor people, who mostly live in remote 
areas of Africa, it was of primary importance to build intertwined governance 
between central and local levels. All of the DDPs analyzed have well-defined 
governance, where each body involved has a specified role and responsibilities, 
as shown in table 4.1. Among the three programmes analyzed, MDP 






Table 4.1 DDPs governance, objective and partnerships. 
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Qualitative evaluations of programme management were carried out for MDP 
and ITI, but so far, there has been no qualitative assessment of GPELF 
activities. Two different evaluations were, however, performed for MDP, 
assessing CDTI sustainability on one side, and governance and partnership 
management on the other.  
Results from studies exploring CDTI performances show that at community 
level, over 70% of projects were positively perceived (51). 
In 2004 Burnham and Mebrathu conducted a study based on semi-structured 





involved. The results showed a positive perception of collaboration between 
local and international bodies. The clear separation between the stakeholders is 
perceived as a contributing factor for programme success. The major issues 
raised regard record gaps among the APOC communities and monitoring 
activities at OCP level (33).  
ITI has also undertaken a qualitative evaluation of its activities. Not only 
successful achievements emerged, but also key issues, including a lack of 
detailed data about trachoma endemicity. This lack of data represents one of the 
major obstacles to programme planning, seen as a poor monitoring activity of 
the SAFE strategy. Furthermore, despite the efforts made, inadequate water and 
sanitation remain a major problem in all programme areas (71).  
MDP, ITI and GPELF have successfully implemented PC, which is also being 
used in the case of schistosomiasis and soil-transmitted helminthiasis, thus 
ensuring a high level of coverage. PC inclusion criteria were based on the 
disease features, and a specific tool for the disease detection was developed, as 
















 Table 4.2 MDA features and diseases burden. 



















































*the following are not eligible: pregnant women and children weighting <15 kg 
Among the various methods used to implement drug delivery strategies, CDT 
seems to be the most cost effective distribution method. CDT was originally 
introduced by APOC for the distribution of ivermectin and subsequently used 
by other DDPs for the control of LF and malaria; however, it has not been 
clearly recognized for the control of trachoma. CDT represents one of the most 
important interventions used to fight NTDs, being sustainable, highly cost-
effective and feasible. Its cost effectiveness has been reported in different 
studies.  
In a three-year multi-country study APOC assessed the sustainability of 
community directed intervention (CDI) from 2005, to understand if CDI could 
be used to fight other diseases in communities with prior CDTI experience. The 
study showed that the CDI approach was more effective than the one currently 





insecticide-treated nets (ITN) for malaria prevention, vitamin A 
supplementation, ivermectin for onchocerciasis, except for short course 
directly-observed treatment of tuberculosis (DOTS). Moreover, without any 
increase in implementation costs, the CDI process achieved higher coverage for 
different interventions (90) 
Other interesting evidence derived from a study conducted in Ghana to assess 
the role of CDT in achieving a higher coverage rate for LF elimination. The 
study showed that the various communities and health staff appreciated the fact 
that CDT was much more involved in regular public-health services at 
implementation level (ComDT/HS) than the mass treatment in which only the 
health services participated (HST). The treatment coverage achieved by 
ComDT/HS was much higher (74.5%) than that of the health system (HST) 
(43.5%) (91). 
Willingness to pay (WTP) gives a comprehensive insight into how people value 
a health intervention. WTP studies analyzed gave mixed results. For example, 
one such study investigating the WTP for prevention and treatment of LF in 
Haiti shows that, although most of the community placed a positive value on 
both of these aspects, 7% of households were not willing to pay for prevention 
while 39% were unwilling to pay for treatment, therefore, any cost recovery 
policy would probably result in inadequate participation and limited 
sustainability (92). 
A baseline survey carried out in two villages in Nigeria showed that 93.3% and 
92.6% of the households in Achi and Nike, respectively, were willing to pay for 
ivermectin distribution, with the mean willingness to pay per dose equaling 
$0.30 in Achi and $0.28 in Nike. As the level of willingness to pay reaches the 
cost of programme implementation, a sustainable programme becomes 





An important aspect that enforces the sustainability of CDT strategy is the 
ability to involve local communities. This involvement could lead to an 
increased awareness of the disease, encouraging the communities to take a 
greater interest in making decisions, which would, in turn, help them to feel 
more responsible and understand how important it is to get treatment. 
CDT is focused on encouraging communities to take responsibility for drug 
delivery, deciding how, when and by whom the treatment should be 
administered, as well as choosing their CDDs (38). Moreover, the people 
directly involved in CDTI are usually volunteers, often involved in other health 
interventions, which contributes to the cost-effectiveness of this type of strategy 
(21). 
An important parameter commonly used for weighting the burden of NTDs is 
DALY, whose available data are often uncertain, not up-dated and incongruent. 
This can be explained by the fact that the estimation of DALYs is a sum of 
different elements, including the amount of population affected, population 
treated and the burden of the disease, in terms of number of people dying from 
the disease or living with the disability.  According to Burton these data are not 
always easy to estimate (93). 
The number of DALYs reported by different authors is taken from the Global 
Health Reports and calculations are made by WHO. All papers report the 










      Table 4.3 DALYs referred to Global Health Report, 2004. 
Diseases DALY 2004* DALY up-date 
**2004 
Onchocerciasis 484,000 389,000 
LF 5,800,000 5,941,000 
Trachoma 2,300,000 1,334,000 
*according to WHO Health Report, 2004. http://www.who.int/whr/2004/en/ 
**WHO Library Cataloguing-in-Publication Data The global burden of disease: 
2004 update. World Health Organization, 2008. 2004 data updated in 2008. 
 
These data have been up-dated in 2008: with calculations of YLL and YLD 
using an additional 3% of time discounting, and non-uniform age weights that 
give less weight to years lived at younger and older ages. A complete update 
was undertaken for estimated deaths by age, sex and cause for all WHO 
Member States. There were 192 Member States in 2004 (95). 
The latest DALYs published by WHO refer to the year 2010 (96) as showed in 
table 4.4. However, because these estimates draw on the results of the Global 
Burden of Disease (GBD) 2010 study, the estimates for the years 2000-2011 are 
not directly comparable with the previous WHO estimates of DALYs for the 
year 2004 or earlier. A simple form of DALY used by the GBD of 2010 study 
has been adopted; age weighting and time discounting are dropped; the YLDs 
are calculated from prevalence estimates rather than incidence estimates, and 
YLDs are also adjusted for independent comorbidity. The standard life table 
used to calculate the years of life lost due to death at a given age is based on the 
projected frontier life expectancy for 2050, with life expectancy of 92 years at 
birth. Differences between these estimates and those previously published by 





estimates from earlier years are not generally comparable due to changes in 
methods and data. In particular, the main DALY estimates published by WHO 
in the past, incorporated age-weighting and time discounting (97). 
 
Table 4.4 DALY, according to the Global Health Report,  
2000-  2011. 











4.2. Economic impact 
As regards the economic evaluations, there is a general lack of standardization 
in the presentation of cost estimates; the inclusion criteria are not standardized; 
many studies do not adequately specify the time period during which data were 
collected, whether the costs were economic or financial; nor do they define the 
year and currency in which results are presented. Due to these methodological 
caveats, direct comparison among studies is challenging. Much of the literature 
about control and treatment costs for these diseases is dated, especially in the 
case of MDP, limiting the possibility to compare costs and cost-effectiveness 
for the different interventions and studies (98).  
Most of the economic studies scrutinised used the loss of productivity due to 





parameter to calculate the economic burden of diseases, and the majority of 
studies calculating the economic costs of the programs did not include drug 
costs. The economic value of a programme have been mainly evaluated through 
cost per DALY averted. 
Referring to MDP, several studies have evaluated the cost of MDA either as 
part of OCP activities or as part of the APOC activities, with the CDTI costs 
and cost per DALYs averted (34, 42, 44-47). Studies regarding the cost of 
MDA based on CDTI for onchocerciasis vary significantly, ranging from a 
financial cost of US$0.20 per person in Nigeria (48), to a MDA cost through 
CDTI in Uganda estimated to be between US$0.13 to US$1.20 across the 
district (38). The main driver of this variation was thought to be the size of the 
population, suggesting that there may be economies of scale when CDTI is 
conducted in more heavily populated areas. It has been estimated that the cost 
of treatment decreases when it is distributed through the CDTI and when it is 
associated with LF, schistosomiasis and soil transmitted helminth infection. 
This can be explained assuming that both economies of scope and scale coexist 
with co-administration and when addressed to a wider population (98). 
Coffeng estimated a total 8.2 million DALYs averted at a cost of US$257 
million thanks to APOC activities, in a time frame of 15 years (1995-2010). He 
estimated the MDA cost per DALY averted at US$31, considering the 
programme to be highly cost-effective (44). Remme, considering the same time 
frame of 15 years within the APOC areas, calculated the total MDA cost 
through CDTI at US$209 million (45). The CDTI cost per DALY averted has 
been assessed by several authors, giving variable results: Remme calculated it 
at US$7, Conteh $9, and Laxminarayan at US$6 per DALY averted (45-47). 
Turner estimated a total amount of $41,536 the annual cost of CDTI for 





in 2004 defined the ivermectin distribution cost per DALY prevented at $14-30 
(42). Coffeng reports treatment cost at US$0.51, and WHO assessed the cost 
per person treated with ivermectin at $0.57, yielding an ERR at 17% (44). A 
result comparable with that obtained from the studies conducted by Kim and 
Benton in 1995 that calculated an ERR of 18% over a time horizon of 39 years 
(43). The average cost per person treated, including volunteer’s time reported 
by Basanez is $0.74 per person (99).  
Onwujekwe reports treatment cost at $0.17 and $0.13 per dose in two villages 
in Nigeria. This estimate includes the direct financial costs, opportunity costs, 
advocacy, mobilizing the community, training and distribution (48). 
It is important to highlight that the donation of drugs at no cost is the main 
factor that makes this a highly cost effective intervention. A sensitivity analysis 
conducted by Waters et al. indicated that including the drugs donated by Merck 
in only one year, valued at market prices, would outweigh the economic 
benefits of the OCP and APOC programs over their lifetimes. In fact, if the cost 
of ivermectin was calculated at $1.50 per tablet (it is the unit value of 
ivermectin production cited by the MDP) the economic evaluations would not 
be positive (42). 
The amount of ivermectin donated up to 2010 represents a value of US$2.1 
billion, assuming 2.8 tablets per treatment and a commercial price per tablet of 
US$1.50 plus US$0.005 shipping costs (personal communication with Dr. 
A.Hopkins, director of the Mectizan Donation Program). This amount is eight 
times the program costs for coordinating mass treatment. Likewise, the value of 
donated ivermectin for the period 2011–2015, should be an additional US$1.8 
billion. Therefore, mass treatment with ivermectin can only be sustained if, as 






The same consideration can be made for LF; it has been calculated that the 
average delivery cost of MDA per person in Haiti is of US$0.44; but taking into 
consideration the drug donation and purchases, the average cost per person 
increases to US$0.68 (100). 
The economic value of GPELF was investigated by Goldman in two different 
studies: in the study conducted in Haiti he estimated that the MDA delivery 
costs at US$0.44 (100); while in a multi-country study he assessed the financial 
cost per person treated ranging from $0.06 to $2.23, with an economic cost 
ranging from $0.40 to $5.87(85). The main factors that affect the cost variations 
are (i) the aging of MDA programs: in fact MDA program start-up year resulted 
in higher financial and economic costs per person treated; (ii) the size of 
population to treat: once the size of the population increases, the treatment cost 
drops; (iii) the use of volunteers that has the greatest impact on costs. The 
results of this study highlighted that MDA for LF can be considered 
inexpensive compared with the other public health programs. Governments and 
communities represent the major financial contributor for the implementation of 
MDA (85). 
Remme assessed that the cost per DALY averted by using MDA for LF 
treatment varied depending on the duration of MDA, from $4 per DALY 
averted in 6 years, to $8 if MDA lasts for 10 years, and $29 in 30 years of 
activity (86). These results show that the annual MDA to treat the entire “at 
risk” population (for a period long enough to interrupt transmission) is US$4 to 
$8 per DALY averted which can be considered a cost-effective approach for 
eliminating LF in high priority areas. The meta analysis of Chu about the first 8 
years of GPELF activities calculated $21.8 billion of direct economic benefits 
gained over the lifetime considering 31.4 million individuals treated, with an 





The economic studies of trachoma and SAFE strategy are not numerically 
substantial and do not specify which kinds of costs are included. The study 
conducted by Evans assumed a cost of $47 per case of visual impairment 
prevented, excluding the cost of surgery; this predated the introduction of SAFE 
strategy so it cannot be considered for ITI economic impact assessment. 
Conteh’s estimation varies significantly, with costs ranging from $5 to $100 per 
DALY averted, due to the fact that all SAFE activities are included (46).  
Frick assessed the burden of trachoma in two different studies: in the first it 
calculated it at $2.9 billion in lost productivity, rising to $5.3 billion in the latest 
study, considering the productivity lost from blindness to be 100% instead of 
60% (70). 
Several economic studies are focused on the impact of surgery for trichiasis 
resulting in a cost-effective intervention, but this aspect lies outside the object 
of ITI activities (101, 102). 
The economic burden of diseases analyzed depends mostly on the indirect cost 
deriving from lost productivity due to the diseases. In fact, these diseases have 
an important burden in terms of disability, even if all of them are preventable 
and rarely cause death. The impact of onchocerciasis includes lost economic 
productivity, diminished earnings; adverse effects on the labor demand and 
reduced agricultural output. Thanks to the efforts made by the APOC and OCP, 
literature reports an increasing number of productivity labor (103). 
Kim and Benton calculated that the OCP activities improved health among the 
adult population, and thanks to the additional onchocerciasis-free situation 
agricultural and labor productivity have increased generating an estimated $3.7 
billion (45). 
LF rarely causes death, having a huge impact in terms of disability due to 





infection status (98). Blindness in rural Africa has previously been assumed to 
result in an annual productivity loss of US$150 per case. Likewise, the 
productivity loss due to itchiness among coffee plantation workers in an 
Ethiopian site has been estimated at around US$5.32 per month per case (44). 
Cost effectiveness analysis supports priority setting by defining areas of action 
where the greatest health gains can be achieved. In order to define whether or 
not an intervention is cost effective, the WHO, in 1998, developed the CHOICE 
initiative (CHOosing Interventions that are Cost-Effective), with the objective 
of providing policy makers with evidence to help them decide on introducing 
interventions and programmes, which would maximize health with the 
resources available (104). WHO-CHOICE has developed threshold values for 
incremental cost-effectiveness ratio of an intervention. Threshold values are 
calculated in dollars referring to the year 2005, using GDP, deriving three 
categories of cost-effectiveness: 
• Highly cost effective (less than per capita GDP); 
• Cost effective (between one and three times per capita GDP); 
• No cost-effective (more than three times per capita GDP). 
The World Bank arbitrarily established another evaluation criteria, defined a 
health intervention that costs less than US$100 per year of life saved as highly-
cost effective for poor countries. Moreover an ERR of 10% was considered by 
the World Bank as a standard for successful public health programmes.  
According to these parameters Molyneux affirmed that controlling NTDs is a 
cost effective strategy, with an annual ERR ranging from 14-30% (105). The 
low cost of treatment per DALY averted, and the affordable total costs required 





It has been reported that DALYs calculation can lead to a total DALY burden 
that might be underestimated, leading to an unrealistic estimation of cost-
effectiveness (18, 46).  
The studies about the burden of trachoma have several weaknesses. First, the 
limited supply of reliable data on the prevalence of disease sequelae in the 
endemic population. Secondly, there are relatively few robust population-based 
surveys that can be used to estimate the number of people affected (93). 
The estimates of cost and the benefits of onchocerciasis control did not include 
the effect on OSD. Hence, these rates underestimate the benefits, because 
itching is a severe morbidity caused by onchocerciasis that accounts for more 
than 50% of the DALYs attributable to onchocerciasis (106). 
Conteh argues that DALYs might not adequately indicate the severity of many 
neglected tropical diseases and the effect on an individual’s quality of life and 
subsequent DALY scores. For example APOC treats only hyper-endemic and 
meso-endemic communities; hence, the number of infected individuals in hypo-
endemic communities (i.e. <40% prevalence of infection), and the burden of 
eye and skin disease in those areas is not known. Many populations in the 
poorest areas are also polyparasitized, a phenomenon not previously assessed in 
terms of disease-burden calculations (46). 
The treatment donated for onchocerciasis, trachoma and LF account for an 
average $0.46 per person treated, considering also the long-term period of 
operation (107). 
Some estimates show that NTDs in sub-Saharan Africa can be treated at a rate 
of $0.40 to $0.79 per patient, accounting for a total $204 million per year on the 
continent (108, 109).  
The costs for treating NTDs are much lower than treatment costs for 





estimated to be an average of $0.50 per person per year, to those for HIV/AIDS 
that can exceed $700 per person per year, and compared to the estimated $6.64 
to treat one case of malaria, it appears evident that addressing NTDs is 
extremely cost effective (15). These affordable costs depend on important 
factors: the drugs are donated free of charge; the use of volunteers, especially at 
local level, who are often not paid; the possibility of synergizing delivery 
treatments (46). The DDPs have been positively influenced from the economies 
of scale, because increasing the size of a programme up to a defined threshold 
reduces the average unit cost. Also the economies of scope play an important 
role in the efficiency of programmes. In fact, when a strategy can be associated 
and implemented along with others addressing the same population (110, 111). 
MDA integration is possible due to the overlapping of disease prevalence in 
most African countries that can lead to a reduction in costs, and the optimal use 
of scarce resources. The possibility to implement MDA with the distribution of 
just four treatments through six PPPs, which are able to combat seven of most 
debilitating NTDs, has been recognized as feasible and affordable. It has been 
estimated that for US$200 million annually, approximately 500 million 
Africans could be treated in a four-drug integrated pro-poor package, at 
US$0.40 per patient. Cost saving including delivery could reach an estimated 
25%, and can be combined with vaccinations and vitamin A supplies (107, 
109).  
A study conducted in four districts in Niger compared the cost of an integrated 
PC to control trachoma, schistosomiasis, LF and STH with the cost of a vertical 
PC control. Leslie shows that the average economic cost of an integrated PC 
was US$0.197/treatment excluding drugs, and the financial cost was 
US$0.09/treatment. The average cost of a vertical programme was US$0.167 





Results suggested that integrated programmes had savings of 16% and 21% in 
programme costs in 2008 and 2009, respectively, compared with vertical 
programmes (112).   
This integrated control has led to an optimal use of resources, reducing 
treatment costs and highlighting logistic convenience. The benefits reside also 
at health level, because integration improves the compliance of people affected 
thanks to the integration of administrations, and can also reduce drug resistance 
(12, 15, 57, 110). 
The efforts made by the PPPs established for NTDs, and the increased interest 
at international level, is having a huge positive impact for the million people 
affected and living in LICs, (21). However, despite the efforts to improve health 
access through a vertical programme, health achievements have not improved 
as much as expected because of weak healthcare systems. Even though 
integrating intervention might be a cost effective approach in co-endemic 
countries, the fragile health system represents an obstacle for its inception 
(113).  
In the future, the concept of integration could have a broader application rather 
than the PC control, including access to clean water and sanitation; 
strengthening surveillance, evaluation, and reporting systems; capacity 
building, deployment of new generation control tools; as well as education and 
communication strategies in order to act on the basic causes of NTDs  (18). 
These actions require a thorough change in the health system of LICs, not an 
easy goal to reach due to the weakness of the system and the lack of health 
education. In the case of trachoma, it will take a lot of effort to eliminate it, 
maybe more than the other NTDs analyzed, because a successful elimination of 
trachoma depends not only on treatment but also on external factors that cause 





study carried out on children in 16 communities in Ethiopia shows that the 
infection rate had been reduced from 63.5% to 2.6% after MDA, but returned to 
25.5% 18 months after the treatment ended. In Maly, three years after the MDA 
program had been completed, the prevalence of trachoma increased in one area 
from 3.9% to 7.3% and in another from 2.7% to 8.2% (114,115). 
The DDPs investigated represent a milestone in the partnerships formed to 
tackle NTDs, for the efforts made, the cost effective strategies implemented, the 
millions of people treated and the results reached. The success of NTDs control 
programmes is the result of national government and donor commitment; clear 
objectives; realistic time frames (long enough to obtain positive outcome); use 
of targeted effective interventions; the PPPs for the coordination of the 
programme; long-term stable financing; drug donation; monitoring and 
evaluation systems (106). 
In the PPPs the intervention of the private sector is one of the most important 
elements that turns the DDPs into cost effective interventions. In fact the 
economic success is primarily due to the donation of treatment free of charge, 
as explained before. An important contribution also derives from governments, 
NGOs, and communities that contribute to manage the programme activities, 
and often also intervene financially.   
Huge efforts have been made for NTDs, and after the London Declaration the 
attention of international stakeholders was raised more than ever, but they still 
have to continue, starting with the issues that rose from the past. As remarked 
by WHO, the integration of interventions is of primary importance, in order to 
reduce the costs of implementation and the resources used.  It is of primary 
importance that NTDs become a part of the larger development agenda at 






The step forward in my research is represented by critical qualitative-
quantitative analysis of the issues derived form the DDPs analyzed, with 
particular interest in the economic analysis, in order to assess the factors that 
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